Everest Medicines announced that its shareholders approved all proposed resolutions during an extraordinary general meeting held virtually on February 24, 2026. The company confirmed this development in a recent filing. The resolutions included the formal approval, confirmation, and ratification of the Commercialization Service Agreement with Hasten, initially entered into on December 11, 2025. The associated transactions were also sanctioned by […]















